INHIBRX BIOSCIENCES INC (INBX:NASDAQ)
$84.08 1.695 (2.0574%)
Analysed INHIBRX BIOSCIENCES INC (INBX:NASDAQ) News Sources
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
21-04-2026
yahoo.com
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
20-04-2026
yahoo.com
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls
08-04-2026
yahoo.com
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
19-03-2026
yahoo.com
Inhibrx Announces Participation in Upcoming Scientific Conference
02-03-2026
yahoo.com
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
28-12-2025
yahoo.com
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates
18-12-2025
yahoo.com
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
16-12-2025
yahoo.com
Inhibrx Reports Third Quarter 2025 Financial Results
14-11-2025
yahoo.com
LGND: Target Up On Improved Growth Outlook
10-11-2025
yahoo.com
What is the current price of INHIBRX BIOSCIENCES INC (INBX:NASDAQ)?
The current price of INHIBRX BIOSCIENCES INC (INBX:NASDAQ) is $84.08.
INHIBRX BIOSCIENCES INC (INBX:NASDAQ) absolute price change since previous trading day?
The absolute price change of INHIBRX BIOSCIENCES INC (INBX:NASDAQ) since the previous trading day is $1.695.
INHIBRX BIOSCIENCES INC (INBX:NASDAQ) percentage price change since previous trading day?
The percentage price change of INHIBRX BIOSCIENCES INC (INBX:NASDAQ) since the previous trading day is 2.0574%.
What is the most recent average sentiment score for INHIBRX BIOSCIENCES INC (INBX:NASDAQ)?
The most recent average sentiment score for INHIBRX BIOSCIENCES INC (INBX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for INHIBRX BIOSCIENCES INC (INBX:NASDAQ)?
The most recent sentiment for INHIBRX BIOSCIENCES INC (INBX:NASDAQ) is .
SEC-8K** Filing Available For INHIBRX BIOSCIENCES INC (INBX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.